CD8A and neoplasm: Taken together, the long-term follow-up of the AMPLIFY-201 phase 1 study provides evidence that ELI-002 2P induces potent, polyfunctional CD4+ and CD8+ T cell immunity to mKRAS alongside frequent antigen spreading that may delay tumor recurrence.